目的 探討谷氨酰胺膠囊聯(lián)合美沙拉秦腸溶片治療潰瘍性結(jié)腸炎的效果。方法 回顧性選取河南省洛陽市偃師人民醫(yī)院2020年12月—2021年12月收治的潰瘍性結(jié)腸炎患者137例為研究對象，根據(jù)治療方案分為對照組（n＝69）和試驗組（n＝68），對照組給予美沙拉秦腸溶片治療，每次4片，每天3次，連續(xù)治療1個月；試驗組在對照組基礎(chǔ)上加用谷氨酰胺膠囊治療，每次0.5 g，每天3次，連續(xù)治療1個月。對比兩組患者治療前后血清C反應(yīng)蛋白（CRP）、血沉（ESR）、胰島素生長因子-Ⅰ（IGF-Ⅰ）、白細(xì)胞介素-6（IL-6）、腫瘤壞死因子-α（TNF-α）、轉(zhuǎn)化生長因子-β1（TGF-β1）及潰瘍性結(jié)腸炎活動指數(shù)Sutherland評分，觀察臨床療效及不良反應(yīng)。結(jié)果 治療前，試驗組和對照組的血清CRP、ESR、IGF-Ⅰ、IL-6、TNF-α、TGF-β1測定值差異無統(tǒng)計學(xué)意義（P＞0.05）；治療后，兩組患者血清CRP、ESR、IL-6、TNF-α測定值均較治療前顯著降低（P＜0.05），且治療后試驗組的血清CRP、ESR、IL-6、TNF-α測定值均顯著低于對照組（P＜0.05）；治療后，兩組患者血清IGF-Ⅰ、TGF-β1測定值均較治療前顯著升高（P＜0.05），且試驗組的IGF-Ⅰ、TGF-β1測定值均顯著高于對照組（P＜0.05）；治療前，試驗組和對照組的Sutherland評分差異無統(tǒng)計學(xué)意義（P＞0.05）；治療后，兩組Sutherland評分均較治療前顯著降低（P＜0.05），且試驗組的Sutherland評分顯著低于對照組（P＜0.05）；治療后，試驗組的整體療效分布優(yōu)于對照組，差異具有統(tǒng)計學(xué)意義（P＜0.05）；治療過程中，試驗組的不良反應(yīng)發(fā)生率4.41%與對照組的5.80%對比，差異不具有統(tǒng)計學(xué)意義（P＞0.05）。結(jié)論 谷氨酰胺膠囊聯(lián)合美沙拉秦腸溶片治療潰瘍性結(jié)腸炎較單用美沙拉秦腸溶片具有更好的臨床效果。

Objective To investigate the effect of Glutamine Capsule combined with Mesalazine Enteric Coated Tablets in treatment of ulcerative colitis. Methods A total of 137 patients with ulcerative colitis treated in Yanshi People's Hospital of Luoyang, Henan Province from December 2020 to December 2021 were retrospectively selected as the research objects. According to the treatment plan, they were divided into control group (n=69) and experimental group (n=68). Patients in control group were treated with Mesalazine Enteric Coated Tablets, four tablets each time, three times a day, for one month. On the basis of the control group, patients in experimental group were treated with Glutamine Capsule, 0.5 g each time, three times a day, for one month. The serum C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), insulin growth factor-I (IGF-I), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α), transforming growth factor-β1 (TGF-β1), and the activity index of ulcerative colitis Sutherland score were compared between two groups before and after treatment. Clinical efficacy and adverse reactions of two group were observed. Results Before treatment, there was no significant difference in measured values of serum CRP, ESR, IGF-I, IL-6, TNF-α, TGF-β1 in experimental group and control group (P > 0.05). After treatment, measured values of serum CRP, ESR, IL-6, and TNF-α in two groups were significantly lower than those before treatment (P < 0.05), and measured values of serum CRP, ESR, IL-6 and TNF-α in experimental group were significantly lower than those in control group (P < 0.05). After treatment, measured values of serum IGF-I and TGF-β1 in two groups were significantly higher than those before treatment (P < 0.05), and measured values of serum IGF-I and TGF-β1 in experimental group were significantly higher than those in control group (P < 0.05). Before treatment, there was no significant difference in Sutherland score between the experimental group and the control group (P > 0.05). After treatment, the Sutherland score of the two groups was significantly lower than that before treatment (P < 0.05), and the Sutherland score of the experimental group was significantly lower than that of control group (P < 0.05). After treatment, the overall efficacy distribution of experimental group was better than that of control group, and the difference was statistically significant (P < 0.05). During treatment, the incidence of adverse reactions in experimental group was 4.41%, compared with 5.80% in control group, and the difference was not statistically significant (P > 0.05). Conclusion Glutamine Capsule combined with Mesalazine Enteric Coated Tablets has better clinical effect in treatment of ulcerative colitis than Mesalazine Enteric Coated Tablets alone.

R975